Balrampur Chini Mills' consolidated Q1 FY27 (quarter ended 30 June 2026) revenue rose 6.1% YoY to ₹1,636.79 Cr (₹1,542.27 Cr a year ago), but consolidated PAT — the primary basis — fell 14.4% YoY to ₹44.15 Cr from ₹51.57 Cr, with basic EPS down to ₹2.16 from ₹2.55. Consolidated PAT includes a ₹6.49 Cr equity-accounted profit contribution from associate Auxilo Finserve Private Limited that standalone PAT of ₹38.59 Cr excludes, explaining most of the gap between the two bases this quarter. Sequentially, PAT dropped 72.3% from ₹159.57 Cr in Q4 FY26, but that comparison is not meaningful on its own: sugar is a seasonal business (the company's own filing notes say results "vary from quarter to quarter"), and Q4 (Jan-Mar) captures the bulk of the crushing/sales season, so the QoQ collapse is a structural seasonality artifact rather than a deterioration signal. No exceptional items appear in either the current or year-ago quarter, so both PAT comparisons are on a like-for-like reported basis.
Operating margin (EBITDA/revenue) compressed to 6.96% from 8.70% a year ago, and net margin to 2.67% from 3.33% (both far below Q4's seasonally elevated 17.75%/9.87%). The squeeze sits mainly below the input-cost line: employee costs rose 7.2% YoY to ₹99.68 Cr and other expenses jumped 25.7% YoY to ₹115.11 Cr, while finance costs eased slightly to ₹32.48 Cr from ₹33.67 Cr. By segment, sugar — still the core earnings driver — posted PBT of ₹38.76 Cr, down 19.4% YoY (₹48.07 Cr) even as sugar segment revenue grew to ₹1,225.27 Cr from ₹1,167.63 Cr, pointing to a realisation/cost squeeze rather than a volume problem.
The PLA (bioplastics) business at the centre of the diversification push flagged in the prior concall saw revenue scale to ₹17.44 Cr from just ₹0.26 Cr a year ago as the Kumbhi plant ramps toward its guided Q3 FY27 commissioning, but the segment's loss widened to ₹9.84 Cr from ₹4.01 Cr YoY — consistent with pre-commissioning ramp costs. On funding, the company completed its guided ₹450 Cr preferential allotment (9.32 Cr shares at ₹483 each) during the quarter and has utilised ₹170.74 Cr of the proceeds toward stated capex objects, with ₹279.26 Cr still parked in deposits/mutual funds; the "Preferential Issue Proceeds Utilized as Planned" disclosure this quarter confirms the funding plan is on track with prior guidance. Management gave no numeric P&L guidance in its prior commentary — the last concall focused on PLA capex cost, funding structure and promoter stake, not revenue or margin targets — so there is no formal outlook to grade growth/margins against, and no separate press release accompanied this filing. Our pre-result preview had flagged sugar realisation, Kumbhi capex economics and the FY27 margin-recovery narrative as the quarter's key watch items alongside Street's Strong Buy consensus (0-7% upside); the realisation/margin question resolved unfavourably (both OPM and NPM contracted YoY), while the preview's on-plan revenue range of ~₹850-900 Cr proved well below the ₹1,636.79 Cr actually reported — a large revenue beat that nonetheless came with a profit miss relative to the growth trajectory a Strong Buy thesis implies.
Going into Q2 FY27, the two swing factors are whether PLA segment losses start narrowing as the plant nears commercial commissioning, and whether sugar segment margins recover as the new crushing season's cost/realisation mix plays out — a quarter with revenue growth but shrinking profitability is a caution flag on cost control heading into the more consequential quarters ahead.
